Ad
related to: alcon novartis deal list of products near me
Search results
Results From The WOW.Com Content Network
Alcon Inc. ( German: Alcon AG) is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people. [2]
The companies agreed on the deal on April 6, 2008. Alcon is the world's largest and most profitable eye care company, Novartis said in a statement, with 2009 annual sales of $6.5 billion and net ...
In 2008 Nestlé sold 24.8% of existing Alcon shares to the Swiss pharmaceutical giant Novartis. In 2010 Nestlé sold the remaining 52% of its Alcon shares to Novartis. Novartis paid a total of 39.1 bn USD. Former brands. This is a selected list of the former brands formerly owned, discontinued, or sold to another company by Nestlé.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
Novartis (NYS: NVS) has two things to say. It now expects more bang for its buck from Alcon. The eye-care acquisition, which cost Novartis $51 billion, will deliver high single-digit to low double ...
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday. Privately held Ivantis Hydrus Microstent makes ...
Ad
related to: alcon novartis deal list of products near me